Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
April 2023
Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...
Walvax Biotechnology’s RQ3013 mRNA Vaccine Shows Efficacy in Phase III Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the efficacy interim results of a...
NMPA’s 2022 Drug Supervision Report: Clinical Trials and Market Filings on the Rise
The National Medical Products Administration (NMPA) has released its “Annual Drug Supervision and Administration Statistics...
Alcon Laboratories’ Innovative Intraocular Lens Approved by China’s NMPA
The National Medical Products Administration (NMPA) has granted import approval to US firm Alcon Laboratories,...
Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma
Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...
EOC Pharma Group Partners with China National Accord Medicines for Distribution Rights
China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord...
Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform
Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...
Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System
Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens...
Shandong Jincheng Pharmaceutical Initiates Phase II Study for LT-01 Antibacterial Drug
Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), China’s largest cephalosporin manufacturer, has announced receiving...
RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System
RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...
Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...
Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China
China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...
Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...
National Center Reports Increase in Medical Device Adverse Event Reports for 2022
The National Center for Adverse Event Monitoring has released its national annual report regarding the...
China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog
The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...
China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab
China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...
XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor
XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment...
Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting
China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...